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Background
Late gadolinium enhancement (LGE) accurately detects
myocardial fibrosis in hypertrophic cardiomyopathy
(HCM), which has been recently shown to be an inde-
pendent risk factor for cardiac events in this setting.
Endoglin is an accessory protein for the TGF-b receptor,
which stimulates myocardial fibrosis through modulat-
ing the response to Angiotensin II. We sought to
explore the relationship between the myocardial fibrosis
( t i s s u es u b s t r a t e )a si d e n t i f i e db yL G Ea n dE n d o g l i n
(biomarker) in the setting of HCM.
Methods
We studied 133 HCM patients (56±16 y, 94 men) using
a whole body 1.5 T CMR scanner (Philips Achieva) with
32 channel image aquisition. Vector-ECG gated short
axis, two and four chamber cine slices with parallel
image aquisition covering the entire left ventricle (LV)
were acquired using a regular SSFP sequence. Matched
LGE images were acquired after IV Gadolinium DTPA
(0.2mmol/kg bodyweight) in all image planes. Two inde-
pendent observers assessed LV volumes and myocardial
mass that were acquired by manual drawing of endo-
and epicardial borders. LGE was defined as signal inten-
sity increase of >2SD of normal myocardium and after
semi-automatic delineation on a commercially available
workstation (Philips Viewforum) areas were quantified
and expressed as percentage of the previously measured
LV mass. Obstruction was determined using echocardio-
graphy gradient measurements at rest and under
Valsalva.
P<0.05 was considered statistically significant.
Results
79 patients (59%) exhibited intramural areas of LGE
which averaged 7±12% of the LV mass. Patients with
LGE had significantly higher levels of Endoglin com-
pared with patients with no LGE lesions (3.8±0.4 vs. 2.4
±0.3 nl, p=0.018). There was a weak but almost signifi-
cant correlation between percent of LGE and Endoglin
(r=0.16, p=0.06). Endoglin levels however were not
related to obstruction (HNCM: 3.7±0.4 vs. 2.8±0.5,
p=ns) and were not related to age, gender or LV mass.
Conclusions
Our results provide preliminary evidence that Endoglin, a
pro-fibrotic glycoprotein may be involved in the pathogen-
esis of late enhancement i.e. myocardial fibrosis in HCM.
This molecular mechanism can have relevant clinical
implications on the therapy of these patients since Endo-
glin expression (and thus probably myocardial fibrosis)
can be suppressed using Angiotensin inhibitors although
further studies on the prognosis and risk stratification of
this new bio-imaging parameter have to be conducted.
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